At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacological Modulation of Hippocampal Activity in Psychosis 2
In Brief
A Phase 2 clinical trial evaluating Levetiracetam (LEV) 500 mg and Placebo for Schizophrenia; Psychosis. Completed, enrolled 62 participants across 1 site.
Detailed Summary
The purpose of this study is to test whether administration of levetiracetam (LEV), a commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal hyperactivity in people with psychotic disorders. Specifically, the investigators will utilize two functional magnetic resonance imaging (MRI) techniques: 1) blood-oxygen-level-dependent (BOLD) contrast will assess activity with a visual scene processing task that engages the anterior hippocampus and 2) arterial spin labeling (ASL) will assess baseline activity. Previous studies in people with psychotic disorders have shown that the hippocampus is hyperactive and more activity correlates with worsening of clinical symptoms. Therefore, the aim of this study is to use an intervention to further understand the underlying mechanisms of the hippocampus in psychosis.
Study Details
Timeline
Interventions
The levetiracetam pill will look just like the placebo pill.
The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.